Literature DB >> 2045037

[Treatment of bacterial vaginitis. Multicenter, randomized, open study with tinidazole in comparison with metronidazole].

E M Schindler1, H Thamm, E B Ansmann, E Sarnow, A E Schindler.   

Abstract

Seventy-five patients, aged between 18 and 55, with clinical bacterial vaginosis were assigned to two treatments in a randomized fashion. One group received a single oral dose of 2 g tinidazole, the other 2 x 1 vaginal tablet of metronidazole 400 mg on five consecutive days. The clinical success rate (healing and improvement) was 97% in the group treated with tinidazole, and 84% in the group treated with metronidazole. One patient of the tinidazole group and six patients of the metronidazole group had to be given further treatment because of an inadequate response to therapy. Although there were no statistically significant differences between the two groups with respect to clinical effect and tolerance, the results do show that, for the treatment of bacterial vaginosis, a single dose of tinidazole represents a clinically effective and well-tolerated therapy that is minimally stressful for the patient and is particularly suitable for prescription by the practicing physician.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2045037

Source DB:  PubMed          Journal:  Fortschr Med        ISSN: 0015-8178


  3 in total

1.  Tinidazole in the treatment of bacterial vaginosis.

Authors:  Nicola R Armstrong; Janet D Wilson
Journal:  Int J Womens Health       Date:  2010-08-09

2.  A comparative study of oral single dose of metronidazole, tinidazole, secnidazole and ornidazole in bacterial vaginosis.

Authors:  Jyoti Thulkar; Alka Kriplani; Nutan Agarwal
Journal:  Indian J Pharmacol       Date:  2012-03       Impact factor: 1.200

3.  Randomized, double-blind, comparative study of oral metronidazole and tinidazole in treatment of bacterial vaginosis.

Authors:  Indu M Raja; Asha Basavareddy; Deepali Mukherjee; Bikash Ranjan Meher
Journal:  Indian J Pharmacol       Date:  2016 Nov-Dec       Impact factor: 1.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.